Sienna stock soars after $65 million IPO
Westlake Village biotechnology company Sienna Biopharmaceuticals closed with a big gain after it raised $65 million in its initial public offering July 27. Sienna priced the 4.33 million shares it offered at $15. Shares had reached $21 around noon before ending at $19.25, a 28.3 percent premium on its opening price. The company operates in Read More →
Deckers Brands sales up 20 percent year-over-year
Deckers Brands reported a 20.3 percent year-over-year net increase in sales but still had a net loss of $42.1 million for its fiscal first quarter ended June 30. Sales continued to grow in its direct-to-consumer channel, including its Hoka One One brand, and the figure included wholesale shipments of Ugg products originally expected to ship Read More →
MindBody revenues up but net losses continue
Consistent with its last earnings report, MindBody’s revenues increased 31 percent for its second fiscal quarter 2017, but net losses persisted, reaching $4.4 million, or 10 cents per basic and diluted share. The San Luis Obispo-based software provider for the wellness industry brought in $44.1 million in revenue, including $17.6 million from its payments software. Read More →
Goleta medical device maker stocks are hot
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
American Riviera Bank sets sights on Paso Robles
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s Kyprolis found to increase cancer survival rate
A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →
